Skip to main content
Top
Published in: Clinical Reviews in Bone and Mineral Metabolism 3/2012

01-09-2012 | Original Paper

Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder

Authors: Kraiwiporn Kiattisunthorn, Sharon M. Moe

Published in: Clinical & Translational Metabolism | Issue 3/2012

Login to get access

Abstract

Over the past decade there has been an increasing awareness of the complexity of bone and mineral complications observed in chronic kidney disease (CKD) and recognition that the consequences of these abnormalities affect not only the skeleton, but also the cardiovascular system. These scientific advances led to the naming of a systemic disorder, “Chronic Kidney Disease-Mineral Bone Disorder” (CKD-MBD) defined as abnormalities in mineral-related biochemistries, bone modeling/remodeling and strength, and extraskeletal calcification. CKD-MBD begins early in the course of progressive CKD, at estimated glomerular filtration rates of 60 ml/min or earlier, with progression such that all dialysis patients have one or more components. The older term, renal osteodystrophy is one component of CKD-MBD and should be used exclusively to define the histopathologic abnormalities of CKD-related bone remodeling. This diagnostic criteria has been further refined using a new classification system “turnover, mineralization, and volume”, that defines bone turnover, mineralization, and volume to allow for a more complete evaluation of renal osteodystrophy. The recognition of this inter-relationship between biochemical changes, bone, and extraskeletal calcification as the systemic disorder CKD-MBD allows for enhanced communication, increased awareness/diagnosis, and improved treatment approaches with the ultimate goal of improving morbidity and mortality in patients with CKD.
Literature
1.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
2.
go back to reference Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213–6.PubMedCrossRef Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213–6.PubMedCrossRef
3.
go back to reference Herzog CA, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80:572–86.PubMedCrossRef Herzog CA, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80:572–86.PubMedCrossRef
4.
go back to reference Lau WL, Pai A, Moe SM, Giachelli CM. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis. 2011;18:105–12.PubMedCrossRef Lau WL, Pai A, Moe SM, Giachelli CM. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis. 2011;18:105–12.PubMedCrossRef
5.
go back to reference Braun J, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394–401.PubMedCrossRef Braun J, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394–401.PubMedCrossRef
6.
go back to reference Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest. 2006;36(Suppl 2):51–62.PubMedCrossRef Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest. 2006;36(Suppl 2):51–62.PubMedCrossRef
7.
go back to reference Raggi P, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005;20:764–72.PubMedCrossRef Raggi P, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005;20:764–72.PubMedCrossRef
8.
go back to reference London GM, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943–51.PubMedCrossRef London GM, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943–51.PubMedCrossRef
9.
go back to reference Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.PubMedCrossRef Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.PubMedCrossRef
10.
go back to reference Moe SM et al. The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011. doi:10.1002/jbmr.485. Moe SM et al. The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011. doi:10.​1002/​jbmr.​485.
11.
14.
go back to reference Kuro OM. Phosphate and klotho. Kidney Int Suppl. 2011;121:S20–3. Kuro OM. Phosphate and klotho. Kidney Int Suppl. 2011;121:S20–3.
15.
go back to reference Hu MC, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22:124–36.PubMedCrossRef Hu MC, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22:124–36.PubMedCrossRef
16.
go back to reference Alem AM, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–9.PubMedCrossRef Alem AM, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–9.PubMedCrossRef
17.
go back to reference Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115–21.PubMedCrossRef Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36:1115–21.PubMedCrossRef
18.
go back to reference Danese MD, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47:149–56.PubMedCrossRef Danese MD, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47:149–56.PubMedCrossRef
19.
go back to reference Stehman-Breen CO, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:2200–5.PubMedCrossRef Stehman-Breen CO, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:2200–5.PubMedCrossRef
20.
go back to reference Atsumi K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33:287–93.PubMedCrossRef Atsumi K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33:287–93.PubMedCrossRef
21.
go back to reference Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74:721–31.PubMedCrossRef Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74:721–31.PubMedCrossRef
22.
go back to reference Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis. 2008;51:38–44.PubMedCrossRef Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis. 2008;51:38–44.PubMedCrossRef
23.
go back to reference Dukas L, Schacht E, Stähelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int. 2005;16:1683–90. Dukas L, Schacht E, Stähelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int. 2005;16:1683–90.
24.
go back to reference Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17:3223–32. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17:3223–32.
25.
go back to reference Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167:133–9. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167:133–9.
26.
go back to reference Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22:503–8. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22:503–8.
27.
go back to reference Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18:282–6. Fried LF, Biggs ML, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18:282–6.
28.
go back to reference Cole JH, van der Meulen MC. Whole bone mechanics and bone quality. Clin Orthop Relat Res. 2011;469:2139–49.PubMedCrossRef Cole JH, van der Meulen MC. Whole bone mechanics and bone quality. Clin Orthop Relat Res. 2011;469:2139–49.PubMedCrossRef
29.
go back to reference Kreider JM, Goldstein SA. Trabecular bone mechanical properties in patients with fragility fractures. Clin Orthop Relat Res. 2009;467:1955–63.PubMedCrossRef Kreider JM, Goldstein SA. Trabecular bone mechanical properties in patients with fragility fractures. Clin Orthop Relat Res. 2009;467:1955–63.PubMedCrossRef
30.
go back to reference Nickolas TL, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21:1371–80.PubMedCrossRef Nickolas TL, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21:1371–80.PubMedCrossRef
31.
go back to reference Sherrard DJ, et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int. 1993;43:436–42.PubMedCrossRef Sherrard DJ, et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int. 1993;43:436–42.PubMedCrossRef
32.
go back to reference Jorgetti V. Review article: bone biopsy in chronic kidney disease: patient level end-point or just another test? Nephrology (Carlton). 2009;14:404–7.CrossRef Jorgetti V. Review article: bone biopsy in chronic kidney disease: patient level end-point or just another test? Nephrology (Carlton). 2009;14:404–7.CrossRef
33.
go back to reference Batista DG, et al. The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances. Calcif Tissue Int. 2010;87:60–7.PubMedCrossRef Batista DG, et al. The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances. Calcif Tissue Int. 2010;87:60–7.PubMedCrossRef
34.
go back to reference Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transpl. 1996;11(Suppl 3):111–20.CrossRef Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transpl. 1996;11(Suppl 3):111–20.CrossRef
35.
go back to reference Barreto FC, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 2006;69:1852–7.PubMedCrossRef Barreto FC, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 2006;69:1852–7.PubMedCrossRef
36.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Clinical practice guidelines for the management of CKD-MBD. Kidney Int. 2009;76:S1–30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Clinical practice guidelines for the management of CKD-MBD. Kidney Int. 2009;76:S1–30.
37.
go back to reference Kazama JJ, et al. Cancellous bone volume is an indicator for trabecular bone connectivity in dialysis patients. Clin J Am Soc Nephrol. 2010;5:292–8.PubMedCrossRef Kazama JJ, et al. Cancellous bone volume is an indicator for trabecular bone connectivity in dialysis patients. Clin J Am Soc Nephrol. 2010;5:292–8.PubMedCrossRef
38.
go back to reference Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26:622–31.PubMedCrossRef Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26:622–31.PubMedCrossRef
39.
go back to reference Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:506–12.PubMed Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:506–12.PubMed
40.
go back to reference Barreto FC, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771–7.PubMedCrossRef Barreto FC, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771–7.PubMedCrossRef
41.
go back to reference Monier-Faugere MC, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460–8.PubMedCrossRef Monier-Faugere MC, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460–8.PubMedCrossRef
42.
go back to reference Salusky IB, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801–8.PubMedCrossRef Salusky IB, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801–8.PubMedCrossRef
43.
go back to reference Zidehsarai MP, Moe SM. Review article: chronic kidney disease-mineral bone disorder: have we got the assays right? Nephrology (Carlton). 2009;14:374–82.CrossRef Zidehsarai MP, Moe SM. Review article: chronic kidney disease-mineral bone disorder: have we got the assays right? Nephrology (Carlton). 2009;14:374–82.CrossRef
44.
go back to reference Joly D, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51:987–95.PubMedCrossRef Joly D, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51:987–95.PubMedCrossRef
45.
go back to reference Fine RN. Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective. Pediatr Nephrol. 2010;25:725–32.PubMedCrossRef Fine RN. Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective. Pediatr Nephrol. 2010;25:725–32.PubMedCrossRef
46.
go back to reference Furth SL, et al. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17:450–5.PubMedCrossRef Furth SL, et al. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17:450–5.PubMedCrossRef
47.
go back to reference Raggi P, et al. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol. 2008;52:17–23.PubMedCrossRef Raggi P, et al. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol. 2008;52:17–23.PubMedCrossRef
48.
go back to reference Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438–41. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438–41.
49.
go back to reference Caliskan Y, et al. Coronary flow reserve dysfunction in hemodialysis and kidney transplant patients. Clin Transplant. 2008;22:785–93.PubMedCrossRef Caliskan Y, et al. Coronary flow reserve dysfunction in hemodialysis and kidney transplant patients. Clin Transplant. 2008;22:785–93.PubMedCrossRef
50.
go back to reference Gullu H, et al. Interrelationship between noninvasive predictors of atherosclerosis: transthoracic coronary flow reserve, flow-mediated dilation, carotid intima-media thickness, aortic stiffness, aortic distensibility, elastic modulus, and brachial artery diameter. Echocardiography. 2006;23:835–42.PubMedCrossRef Gullu H, et al. Interrelationship between noninvasive predictors of atherosclerosis: transthoracic coronary flow reserve, flow-mediated dilation, carotid intima-media thickness, aortic stiffness, aortic distensibility, elastic modulus, and brachial artery diameter. Echocardiography. 2006;23:835–42.PubMedCrossRef
51.
go back to reference London GM, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl. 2003;18:1731–40.CrossRef London GM, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl. 2003;18:1731–40.CrossRef
52.
go back to reference Mehrotra R, et al. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68:1258–66.PubMedCrossRef Mehrotra R, et al. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68:1258–66.PubMedCrossRef
53.
go back to reference Block GA, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–24.PubMedCrossRef Block GA, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–24.PubMedCrossRef
54.
go back to reference Moe SM, et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transpl. 2004;19:2387–93.CrossRef Moe SM, et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transpl. 2004;19:2387–93.CrossRef
55.
go back to reference Schwarz U, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transpl. 2000;15:218–23.CrossRef Schwarz U, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transpl. 2000;15:218–23.CrossRef
56.
go back to reference Gross ML, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and X-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2007;2:121–34.PubMedCrossRef Gross ML, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and X-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2007;2:121–34.PubMedCrossRef
57.
go back to reference Nakamura S, et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009;4:1892–900.PubMedCrossRef Nakamura S, et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009;4:1892–900.PubMedCrossRef
58.
go back to reference Moe SM, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638–47.PubMedCrossRef Moe SM, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638–47.PubMedCrossRef
59.
go back to reference Jono S, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–7.PubMedCrossRef Jono S, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–7.PubMedCrossRef
60.
go back to reference Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003–11.PubMedCrossRef Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003–11.PubMedCrossRef
61.
go back to reference Ketteler M, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827–33.PubMedCrossRef Ketteler M, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827–33.PubMedCrossRef
62.
go back to reference O’Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transpl. 2010;25:187–91.CrossRef O’Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transpl. 2010;25:187–91.CrossRef
63.
go back to reference Luo G, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81.PubMedCrossRef Luo G, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81.PubMedCrossRef
64.
go back to reference Hermans MM, et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif. 2007;25:395–401.PubMedCrossRef Hermans MM, et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif. 2007;25:395–401.PubMedCrossRef
65.
go back to reference Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int. 2009;76:18–22.PubMedCrossRef Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int. 2009;76:18–22.PubMedCrossRef
66.
go back to reference Moe SM, et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009;75:176–84.PubMedCrossRef Moe SM, et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009;75:176–84.PubMedCrossRef
67.
go back to reference Hruska KA, et al. Kidney–bone, bone–kidney, and cell–cell communications in renal osteodystrophy. Semin Nephrol. 2004;24:25–38.PubMedCrossRef Hruska KA, et al. Kidney–bone, bone–kidney, and cell–cell communications in renal osteodystrophy. Semin Nephrol. 2004;24:25–38.PubMedCrossRef
68.
go back to reference Cozzolino M, et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol. 2002;13:2299–308.PubMedCrossRef Cozzolino M, et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol. 2002;13:2299–308.PubMedCrossRef
69.
go back to reference Ohnishi M, Nakatani T, Lanske B, Razzaque MS. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 2009;75:1166–72.PubMedCrossRef Ohnishi M, Nakatani T, Lanske B, Razzaque MS. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 2009;75:1166–72.PubMedCrossRef
70.
go back to reference Neves KR, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007;71:1262–70.PubMedCrossRef Neves KR, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007;71:1262–70.PubMedCrossRef
71.
go back to reference Graciolli FG, et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transpl. 2009;24:1416–21.CrossRef Graciolli FG, et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transpl. 2009;24:1416–21.CrossRef
72.
go back to reference Asci G, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transpl. 2011;26:1010–5.CrossRef Asci G, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transpl. 2011;26:1010–5.CrossRef
73.
go back to reference Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–52.PubMedCrossRef Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–52.PubMedCrossRef
74.
go back to reference Russo D, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–61.PubMedCrossRef Russo D, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–61.PubMedCrossRef
75.
go back to reference Qunibi W, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–65.PubMedCrossRef Qunibi W, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–65.PubMedCrossRef
76.
go back to reference Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26(4):1327–39. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26(4):1327–39.
77.
go back to reference Block GA, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.PubMedCrossRef Block GA, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.PubMedCrossRef
78.
go back to reference Palmer SC, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119–27.PubMedCrossRef Palmer SC, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119–27.PubMedCrossRef
79.
go back to reference Gutierrez OM, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.PubMedCrossRef Gutierrez OM, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.PubMedCrossRef
80.
go back to reference Wolf M, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–13.PubMedCrossRef Wolf M, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–13.PubMedCrossRef
81.
go back to reference Mehrotra R, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76:977–83.PubMedCrossRef Mehrotra R, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76:977–83.PubMedCrossRef
82.
go back to reference Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.PubMedCrossRef Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.PubMedCrossRef
83.
go back to reference Moe SM, Sprague SM. Mineral bone disorder in CKD. In: Brenner BM, Rector FC, editors. The kidney, vol. 2. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 1786. Moe SM, Sprague SM. Mineral bone disorder in CKD. In: Brenner BM, Rector FC, editors. The kidney, vol. 2. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 1786.
Metadata
Title
Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder
Authors
Kraiwiporn Kiattisunthorn
Sharon M. Moe
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Clinical & Translational Metabolism / Issue 3/2012
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-011-9119-1

Other articles of this Issue 3/2012

Clinical Reviews in Bone and Mineral Metabolism 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.